JHL Biotech submits clinical trial application in Europe for proposed bevacizumab biosimilar

December 21, 2017 2:48 PM

JHL Biotech Inc. announced that the company has submitted a Phase I Clinical Trial Application on December 15, 2017 to European authorities for its proposed bevacizumab biosimilar, JHL1149.

JHL1149 is a proposed biosimilar for a biologic used for the treatment of many cancers, the most common of which are metastatic colorectal cancer, lung cancer, and ovarian cancer. In 2016, reference bevacizumab (Avastin – Roche/Genentech) generated revenues of approximately US$7 billion.

JHL is planning to conduct a single-site, three-arm pharmacokinetic study in healthy volunteers. The data from this trial will support the rapid development and commercialization of JHL1149.

“Bevacizumab is an important biologic that is, unfortunately, very expensive. JHL Biotech looks forward to making bevacizumab biosimilar available to all who need it, and our JHL1149 European clinical trial is the first step in achieving this goal,” said Racho Jordanov, JHL Biotech’s CEO.

Source: JHL Biotech Inc press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!